Transforming drug discovery
The Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium is a public-private partnership with the mission of transforming drug discovery by accelerating the development of more effective therapies for patients.
In June 2016, GSK, the Department of Energy, and the National Cancer Institute announced their intent to create the ATOM partnership as one of the Cancer Moonshot task forces, with funding support under the 21st Century Cures Act.
The ATOM consortium was officially established in October 2017.
ATOM founding members are GSK, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco.
Our goal is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and patient-centric model. We are integrating high performance computing, diverse biological data, and emerging biotechnologies to create a new pre-competitive platform for drug discovery.
GSK is providing chemical and in vitro biological data for more than 2 million compounds from its historic and current screening collection, as well as preclinical and clinical information on 500 molecules that have failed in development but provide data that could help advance new, successful compounds. GSK also offers expertise in drug discovery and development, computational chemistry, and biology.
Lawrence Livermore National Laboratory is contributing its best-in-class supercomputers, including its next-generation system Sierra, as well as its expertise and innovative approaches to modeling and simulation, cognitive computing, machine learning, and algorithm development. More broadly, by applying high-performance computing to the ambitious problem of cancer therapy, the Department of Energy and National Nuclear Security Administration hopes to accelerate technologies vital to its core missions.
UC San Francisco is providing expertise from a long-history of innovation in medicine and drug discovery combined with its strengths in cancer and translation of technologies and therapeutics to improve the lives of patients.